New Delhi: In view of the increasing Mpox infections in Central and East Africa, the World Health Organization (WHO) has declared an international health emergency.
The specialty chemicals company LANXESS has claimed that its disinfectant Rely+On Virkon has been proven to be effective against the Mpox virus, formerly known as the “monkeypox virus”.
As per the company, the independent tests have confirmed the product’s effectiveness against the virus.
“Especially in times of rising infection rates, the choice of an effective disinfectant that has been proven to kill the target pathogen is crucial,” says Roy van Wel, Head of the market segment Hygiene and Care at LANXESS.
Rely+On Virkon is used for the disinfection of hard surfaces in hospitals, healthcare facilities, airports, public transportation terminals, clinics, shopping malls and many other public places. It has proven to be effective against the pathogen and supports prevention in risk areas. It provides effective inactivation of the virus on hard surfaces, helping to contain the spread.
Dr Sagar Sengupta, Director, National Institute of Biomedical Genomics (NIBMG) and Director (Additional Charge), National Brain Research Centre (NBRC) shared his insights on the latest initiatives, importance of industry-academia collaboration, increased government funding, and evolution of research ecosystem
Binoy Gardi, Managing Director and Group CEO, Veeda Lifesciences shared insights on his latest role and top priorities; the company's latest initiatives, outcomes of key acquisitions and future plans